Build Your Comparison

Side-by-side financial analysis
WAY logo
WAY
UNH logo
UNH
JPM logo
JPM
CVS logo
CVS
CI logo
CI
Try popular comparisons:

Stock Comparison

WAY vs UNH vs JPM vs CVS vs CI

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
WAY
Waystar Holding Corp.

Information Technology Services

TechnologyNASDAQ • US
Market Cap$3.60B
5Y Perf.-12.8%
UNH
UnitedHealth Group Incorporated

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$370.80B
5Y Perf.-19.8%
JPM
JPMorgan Chase & Co.

Banks - Diversified

Financial ServicesNYSE • US
Market Cap$896.00B
5Y Perf.+58.6%
CVS
CVS Health Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$130.09B
5Y Perf.+72.6%
CI
Cigna Corporation

Medical - Healthcare Plans

HealthcareNYSE • US
Market Cap$78.57B
5Y Perf.-9.9%

WAY vs UNH vs JPM vs CVS vs CI — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
WAY logoWAY
UNH logoUNH
JPM logoJPM
CVS logoCVS
CI logoCI
IndustryInformation Technology ServicesMedical - Healthcare PlansBanks - DiversifiedMedical - Healthcare PlansMedical - Healthcare Plans
Market Cap$3.60B$370.80B$896.00B$130.09B$78.57B
Revenue (TTM)$1.16B$449.71B$280.33B$407.90B$277.94B
Net Income (TTM)$126M$12.04B$57.05B$2.93B$6.29B
Gross Margin65.2%18.8%60.0%13.9%9.3%
Operating Margin24.3%4.2%25.9%1.5%3.4%
Forward P/E11.4x22.2x14.4x13.8x9.8x
Total Debt$1.50B$78.39B$942.38B$93.59B$31.46B
Cash & Equiv.$61M$24.36B$343.34B$8.51B$7.68B

WAY vs UNH vs JPM vs CVS vs CILong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

WAY
UNH
JPM
CVS
CI
StockJun 24Jun 26Return
Waystar Holding Cor… (WAY)10087.2-12.8%
UnitedHealth Group … (UNH)10080.2-19.8%
JPMorgan Chase & Co. (JPM)100158.6+58.6%
CVS Health Corporat… (CVS)100172.6+72.6%
Cigna Corporation (CI)10090.1-9.9%

Price return only. Dividends and distributions are not included.

Quick Verdict: WAY vs UNH vs JPM vs CVS vs CI

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CVS leads in 3 of 7 categories (5-stock set), making it the strongest pick for capital preservation and lower volatility and dividend income and shareholder returns. Cigna Corporation is the stronger pick specifically for valuation and capital efficiency and operational efficiency and capital deployment. WAY and JPM also each lead in at least one category. This set spans 3 sectors — these stocks serve different portfolio roles, not just different price points.
🥇CVS emerged as the overall leader. Track its performance:
WAY
Waystar Holding Corp.
The Growth Play

WAY ranks third and is worth considering specifically for growth exposure.

  • Rev growth 16.5%, EPS growth 5.7%, 3Y rev CAGR 16.0%
  • 16.5% revenue growth vs JPM's 3.3%
Best for: growth exposure
UNH
UnitedHealth Group Incorporated
The Insurance Pick

UNH is the clearest fit if your priority is income & stability.

  • Dividend streak 16 yrs, beta 0.61, yield 2.1%
Best for: income & stability
JPM
JPMorgan Chase & Co.
The Banking Pick

JPM is the clearest fit if your priority is long-term compounding.

  • 465.8% 10Y total return vs CI's 158.0%
  • 20.4% margin vs CVS's 0.7%
Best for: long-term compounding
CVS
CVS Health Corporation
The Insurance Pick

CVS carries the broadest edge in this set and is the clearest fit for defensive.

  • Beta 0.19, yield 2.6%, current ratio 0.84x
  • Beta 0.19 vs JPM's 0.94, lower leverage
  • 2.6% yield, vs UNH's 2.1%, (1 stock pays no dividend)
  • +57.7% vs WAY's -52.6%
Best for: defensive
CI
Cigna Corporation
The Insurance Pick

CI is the #2 pick in this set and the best alternative if sleep-well-at-night is your priority.

  • Lower volatility, beta 0.40, Low D/E 75.1%, current ratio 0.85x
  • Lower P/E (9.8x vs 22.2x)
  • 4.1% ROA vs CVS's 1.1%, ROIC 10.4% vs 5.0%
Best for: sleep-well-at-night
See the full category breakdown
CategoryWinnerWhy
GrowthWAY logoWAY16.5% revenue growth vs JPM's 3.3%
ValueCI logoCILower P/E (9.8x vs 22.2x)
Quality / MarginsJPM logoJPM20.4% margin vs CVS's 0.7%
Stability / SafetyCVS logoCVSBeta 0.19 vs JPM's 0.94, lower leverage
DividendsCVS logoCVS2.6% yield, vs UNH's 2.1%, (1 stock pays no dividend)
Momentum (1Y)CVS logoCVS+57.7% vs WAY's -52.6%
Efficiency (ROA)CI logoCI4.1% ROA vs CVS's 1.1%, ROIC 10.4% vs 5.0%

WAY vs UNH vs JPM vs CVS vs CI — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

Discover the Biotech & Healthcare Stocks Theme

These companies are key players in the Biotech & Healthcare Stocks ecosystem. See how they stack up against the rest of the sector.

Explore Theme
WAYWaystar Holding Corp.
FY 2025
Subscription and Circulation
100.0%$558M
UNHUnitedHealth Group Incorporated
FY 2025
Unitedhealthcare
94.4%$332.4B
Optumhealth
5.6%$19.8B
JPMJPMorgan Chase & Co.
FY 2025
Commercial And Investment Bank
43.0%$78.5B
Consumer & Community Banking
41.7%$76.0B
Asset and Wealth Management Segment
13.2%$24.1B
Segment Reporting, Reconciling Item, Corporate Nonsegment
3.9%$7.0B
Segment Reconciling Items
-1.7%$-3,134,000,000
CVSCVS Health Corporation
FY 2025
Pharmacy Revenue
58.9%$229.0B
Premiums
34.6%$134.8B
Front Store Revenue
5.5%$21.5B
Product and Service, Other
1.0%$3.9B
CICigna Corporation
FY 2025
Evernorth
83.2%$235.0B
Cigna Healthcare
16.8%$47.4B

WAY vs UNH vs JPM vs CVS vs CI — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLJPMLAGGINGUNH

Income & Cash Flow (Last 12 Months)

JPM leads this category, winning 3 of 6 comparable metrics.

UNH is the larger business by revenue, generating $449.7B annually — 388.8x WAY's $1.2B. JPM is the more profitable business, keeping 20.4% of every revenue dollar as net income compared to CVS's 0.7%. On growth, WAY holds the edge at +22.4% YoY revenue growth, suggesting stronger near-term business momentum.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
RevenueTrailing 12 months$1.2B$449.7B$280.3B$407.9B$277.9B
EBITDAEarnings before interest/tax$430M$23.2B$81.4B$10.5B$12.1B
Net IncomeAfter-tax profit$126M$12.0B$57.0B$2.9B$6.3B
Free Cash FlowCash after capex$294M$19.7B$100.9B$7.4B$7.7B
Gross MarginGross profit ÷ Revenue+65.2%+18.8%+60.0%+13.9%+9.3%
Operating MarginEBIT ÷ Revenue+24.3%+4.2%+25.9%+1.5%+3.4%
Net MarginNet income ÷ Revenue+10.9%+2.7%+20.4%+0.7%+2.3%
FCF MarginFCF ÷ Revenue+25.4%+4.4%+36.0%+1.8%+2.8%
Rev. Growth (YoY)Latest quarter vs prior year+22.4%+2.0%+6.2%+4.6%
EPS Growth (YoY)Latest quarter vs prior year+37.5%+0.7%+16.0%+63.1%+29.1%
JPM leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

CI leads this category, winning 4 of 6 comparable metrics.

At 13.4x trailing earnings, CI trades at a 82% valuation discount to CVS's 73.4x P/E. On an enterprise value basis, CI's 8.7x EV/EBITDA is more attractive than JPM's 18.4x.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Market CapShares × price$3.6B$370.8B$896.0B$130.1B$78.6B
Enterprise ValueMkt cap + debt − cash$5.0B$424.8B$1.50T$215.2B$102.4B
Trailing P/EPrice ÷ TTM EPS30.74x30.88x16.00x73.35x13.44x
Forward P/EPrice ÷ next-FY EPS est.11.42x22.21x14.40x13.78x9.79x
PEG RatioP/E ÷ EPS growth rate0.90x
EV / EBITDAEnterprise value multiple12.39x18.21x18.36x14.35x8.70x
Price / SalesMarket cap ÷ Revenue3.27x0.83x3.20x0.32x0.29x
Price / BookPrice ÷ Book value/share0.95x3.66x2.47x1.72x1.89x
Price / FCFMarket cap ÷ FCF12.70x23.07x8.88x16.66x9.37x
CI leads this category, winning 4 of 6 comparable metrics.

Profitability & Efficiency

CI leads this category, winning 4 of 9 comparable metrics.

JPM delivers a 15.9% return on equity — every $100 of shareholder capital generates $16 in annual profit, vs $4 for WAY. WAY carries lower financial leverage with a 0.39x debt-to-equity ratio, signaling a more conservative balance sheet compared to JPM's 2.60x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
ROE (TTM)Return on equity+3.5%+11.5%+15.9%+3.9%+15.1%
ROA (TTM)Return on assets+2.4%+3.9%+1.3%+1.1%+4.1%
ROICReturn on invested capital+4.2%+9.2%+4.5%+5.0%+10.4%
ROCEReturn on capital employed+5.2%+9.7%+8.9%+6.1%+9.2%
Piotroski ScoreFundamental quality 0–956558
Debt / EquityFinancial leverage0.39x0.77x2.60x1.24x0.75x
Net DebtTotal debt minus cash$1.4B$54.0B$599.0B$85.1B$23.8B
Cash & Equiv.Liquid assets$61M$24.4B$343.3B$8.5B$7.7B
Total DebtShort + long-term debt$1.5B$78.4B$942.4B$93.6B$31.5B
Interest CoverageEBIT ÷ Interest expense3.51x4.71x0.74x2.11x6.77x
CI leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

JPM leads this category, winning 4 of 6 comparable metrics.

A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $9,058 for WAY. Over the past 12 months, CVS leads with a +57.7% total return vs WAY's -52.6%. The 3-year compound annual growth rate (CAGR) favors JPM at 33.6% vs UNH's -4.2% — a key indicator of consistent wealth creation.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
YTD ReturnYear-to-date-40.2%+22.1%-0.5%+28.9%+7.9%
1-Year ReturnPast 12 months-52.6%+31.0%+21.8%+57.7%-3.6%
3-Year ReturnCumulative with dividends-9.4%-12.0%+138.2%+53.6%+18.1%
5-Year ReturnCumulative with dividends-9.4%+11.7%+118.2%+35.0%+35.3%
10-Year ReturnCumulative with dividends-9.4%+236.1%+465.8%+29.5%+158.0%
CAGR (3Y)Annualised 3-year return-3.2%-4.2%+33.6%+15.4%+5.7%
JPM leads this category, winning 4 of 6 comparable metrics.

Risk & Volatility

CVS leads this category, winning 2 of 2 comparable metrics.

CVS is the less volatile stock with a 0.19 beta — it tends to amplify market swings less than JPM's 0.94 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.2% from its 52-week high vs WAY's 45.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Beta (5Y)Sensitivity to S&P 5000.84x0.61x0.94x0.19x0.40x
52-Week HighHighest price in past year$41.47$415.96$337.25$102.77$338.89
52-Week LowLowest price in past year$17.89$234.60$262.71$58.50$239.51
% of 52W HighCurrent price vs 52-week peak+45.2%+98.2%+95.1%+99.2%+87.9%
RSI (14)Momentum oscillator 0–10040.366.559.172.659.4
Avg Volume (50D)Average daily shares traded2.4M7.2M7.0M7.6M1.4M
CVS leads this category, winning 2 of 2 comparable metrics.

Analyst Outlook

Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.

Analyst consensus: WAY as "Buy", UNH as "Buy", JPM as "Buy", CVS as "Buy", CI as "Buy". Consensus price targets imply 90.0% upside for WAY (target: $36) vs 1.6% for CVS (target: $104). For income investors, CVS offers the higher dividend yield at 2.62% vs JPM's 1.86%.

MetricWAY logoWAYWaystar Holding C…UNH logoUNHUnitedHealth Grou…JPM logoJPMJPMorgan Chase & …CVS logoCVSCVS Health Corpor…CI logoCICigna Corporation
Analyst RatingConsensus buy/hold/sellBuyBuyBuyBuyBuy
Price TargetConsensus 12-month target$35.62$418.50$339.75$103.64$342.55
# AnalystsCovering analysts1752614139
Dividend YieldAnnual dividend ÷ price+2.1%+1.9%+2.6%+2.0%
Dividend StreakConsecutive years of raises161505
Dividend / ShareAnnual DPS$8.70$5.95$2.67$6.06
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.5%+3.9%0.0%+4.6%
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Key Takeaway

JPM leads in 2 of 6 categories (Income & Cash Flow, Total Returns). CI leads in 2 (Valuation Metrics, Profitability & Efficiency). 1 tied.

Best OverallJPMorgan Chase & Co. (JPM)Leads 2 of 6 categories
Loading custom metrics...

WAY vs UNH vs JPM vs CVS vs CI: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is WAY or UNH or JPM or CVS or CI a better buy right now?

For growth investors, Waystar Holding Corp.

(WAY) is the stronger pick with 16. 5% revenue growth year-over-year, versus 3. 3% for JPMorgan Chase & Co. (JPM). Cigna Corporation (CI) offers the better valuation at 13. 4x trailing P/E (9. 8x forward), making it the more compelling value choice. Analysts rate Waystar Holding Corp. (WAY) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — WAY or UNH or JPM or CVS or CI?

On trailing P/E, Cigna Corporation (CI) is the cheapest at 13.

4x versus CVS Health Corporation at 73. 4x. On forward P/E, Cigna Corporation is actually cheaper at 9. 8x.

03

Which is the better long-term investment — WAY or UNH or JPM or CVS or CI?

Over the past 5 years, JPMorgan Chase & Co.

(JPM) delivered a total return of +118. 2%, compared to -9. 4% for Waystar Holding Corp. (WAY). Over 10 years, the gap is even starker: JPM returned +465. 8% versus WAY's -9. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — WAY or UNH or JPM or CVS or CI?

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

19β versus JPMorgan Chase & Co. 's 0. 94β — meaning JPM is approximately 394% more volatile than CVS relative to the S&P 500. On balance sheet safety, Waystar Holding Corp. (WAY) carries a lower debt/equity ratio of 39% versus 3% for JPMorgan Chase & Co. — giving it more financial flexibility in a downturn.

05

Which is growing faster — WAY or UNH or JPM or CVS or CI?

By revenue growth (latest reported year), Waystar Holding Corp.

(WAY) is pulling ahead at 16. 5% versus 3. 3% for JPMorgan Chase & Co. (JPM). On earnings-per-share growth, the picture is similar: Waystar Holding Corp. grew EPS 569. 2% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, WAY leads at 16. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — WAY or UNH or JPM or CVS or CI?

JPMorgan Chase & Co.

(JPM) is the more profitable company, earning 20. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 20. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JPM leads at 26. 0% versus 2. 6% for CVS. At the gross margin level — before operating expenses — WAY leads at 64. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is WAY or UNH or JPM or CVS or CI more undervalued right now?

On forward earnings alone, Cigna Corporation (CI) trades at 9.

8x forward P/E versus 22. 2x for UnitedHealth Group Incorporated — 12. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for WAY: 90. 0% to $35. 62.

08

Which pays a better dividend — WAY or UNH or JPM or CVS or CI?

In this comparison, CVS (2.

6% yield), UNH (2. 1% yield), CI (2. 0% yield), JPM (1. 9% yield) pay a dividend. WAY does not pay a meaningful dividend and should not be held primarily for income.

09

Is WAY or UNH or JPM or CVS or CI better for a retirement portfolio?

For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), 2. 6% yield). Both have compounded well over 10 years (CVS: +29. 5%, WAY: -9. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between WAY and UNH and JPM and CVS and CI?

These companies operate in different sectors (WAY (Technology) and UNH (Healthcare) and JPM (Financial Services) and CVS (Healthcare) and CI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: WAY is a small-cap high-growth stock; UNH is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; CVS is a mid-cap quality compounder stock; CI is a mid-cap deep-value stock. UNH, JPM, CVS, CI pay a dividend while WAY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.